| Assessment Status | Rapid Review Complete |
| HTA ID | 24045 |
| Drug | Ribociclib |
| Brand | Kisqali® |
| Indication | Ribociclib in combination with an aromatase inhibitor (AI) is indicated for the adjuvant treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. |
| Assessment Process | |
| Rapid review commissioned | 13/11/2024 |
| Rapid review completed | 19/12/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that ribociclib not be considered for reimbursement at the submitted price*. |
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. October 2025